

IP/1632
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 07 2002

In re application of:

Catherine GUENTHER et al.

Application No.: 09/883,093

Filed: June 14, 2001

For: Transgenic Mice Containing Nuclear
Hormone Receptor Gene Disruptions

Examiner: Unassigned

Art Unit: 1632

Atty. Docket No.: R-126

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the examination of the above-referenced application and in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 2, 2002, entry of the following amendment is respectfully requested:

In the Drawings

1/2

Please replace Figure 2A in the application with the enclosed new Figure 2A.

REMARKS

The amendment to Figure 2A merely adds a sequence identifier to the figure to comply with 37 C.F.R. 1.821(d) and does not introduce new matter. Entry of the foregoing amendment is respectfully requested.

Favorable action on the merits is earnestly solicited.

Date: November 1, 2002

Respectfully submitted,

Mariette A. Lapiz
Mariette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
(650) 569-5100

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on **November 1, 2002**

Name: **Deborah A. Mojarrro**

Signed: Deborah A. Mojarrro

Date: 11/1/02